SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Frostegård J) "

Sökning: WFRF:(Frostegård J)

  • Resultat 1-10 av 28
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Nesme, Joseph, et al. (författare)
  • Back to the Future of Soil Metagenomics
  • 2016
  • Ingår i: Frontiers in Microbiology. - : Frontiers Media SA. - 1664-302X. ; 7
  • Tidskriftsartikel (refereegranskat)
  •  
3.
  •  
4.
  • Bennet, A. M., et al. (författare)
  • Association of TNF-α serum levels and TNFA promoter polymorohisms with risk of myocardial infarction
  • 2006
  • Ingår i: Atherosclerosis. - : Elsevier. - 0021-9150 .- 1879-1484. ; 187:2, s. 408-414
  • Tidskriftsartikel (refereegranskat)abstract
    • Elevated levels of tumor necrosis factor-alpha (TNF-α), and presence of polymorphisms of the TNFA gene have been implicated in cardiovascular disease pathogenesis. We explored the relationship between polymorphisms in the TNFA gene (−1031C/T, −863C/A −857T/C, −308G/A, −238G/A), protein levels of TNF-α and their association to myocardial infarction (MI) using a sample of 1213 post-MI patients and 1561 healthy controls. MI risk was higher among men with elevated TNF-α levels, with the highest compared to the lowest TNF-α quartile giving a 70% risk increase (OR [95% CI]: 1.7 [1.1; 2.6]). Obese subjects who also had elevated TNF-α levels were at even higher risk for MI (OR [95% CI]: 3.4 [2.1; 5.6]). Higher TNF-α levels were seen among smokers (but not among non-smokers) carrying the −857T allele. Furthermore, a rare haplotype occurred more frequently among the cases than the controls. Elevated TNF-α levels are associated with increased MI risk. Obese subjects with elevated TNF-a levels, and carriers of polymorphisms in or near TNFA are particularly susceptible to the hazards of smoking, results which may have implications for cardiovascular preventive measures.
  •  
5.
  •  
6.
  • Frostegård, J., et al. (författare)
  • Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus
  • 2018
  • Ingår i: Lupus. - : SAGE PUBLICATIONS LTD. - 0961-2033 .- 1477-0962. ; 27:10, s. 1670-1678
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives In systemic lupus erythematosus (SLE) there are typically many autoantibodies. The disease heterogeneity could be better understood with discovery of phenotype-specific antigens targeted by autoantibodies. We here aimed to identify novel autoantigens potentially related to SLE disease and a major complication, atherosclerosis. Methods Antigen microarrays were used to profile IgG autoantibody reactivity against 77 protein fragments (20-140 amino acids (aa) long, median 89 aa) produced within the Human Protein Atlas project, in serum samples from SLE patients (n=107) and age- and sex-matched population-based controls (n=107). Common carotid intima-media thickness, plaque occurrence and echogenicity were determined by B-mode ultrasound. Results We determined significant differences between patients and controls in IgG reactivity against four proteins. In patients compared to controls, there was an increase of IgG reactivity against zinc finger protein 688 (ZNF688), early B cell factor 2 (EBF2), crystallin, alpha B (CRYAB) and tumor necrosis factor receptor superfamily member 13C (TNFRSF13C). Of these four antigens, only anti-ZNF688 was associated with carotid atherosclerosis (plaque occurrence) and vulnerable plaques in SLE. There was a weak association between anti-EBF2 and SLE disease activity but no significant associations were determined for other measured IgG reactivity. Conclusions In this discovery screening we here demonstrate new candidate autoantigens with differential reactivity (reflecting autoantibody levels) in SLE patients and in controls and in relation to atherosclerosis in SLE.
  •  
7.
  •  
8.
  • Sun, J., et al. (författare)
  • Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6
  • 2021
  • Ingår i: ACR Open Rheumatology. - : Wiley. - 2578-5745. ; 3:9, s. 642-653
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: We study activation of T helper 17 (Th17) and regulatory T (Treg) cells and induction of apoptosis in cells from patients with systemic lupus erythematosus (SLE) compared with controls and effects of atorvastatin and its simulated interactions with other compounds. Methods: Mononuclear cells from 10 patients with SLE and 10 controls were cultured in conditions that induce Th17 and/or Treg cell polarization and/or apoptosis and were studied by FACScan. Gene expression was determined by quantitative real-time reverse transcription–polymerase chain reaction. Cytokines in plasma were determined by enzyme-linked immunosorbent assay. The Search Tool for Interactions of Chemicals (STITCH) was used to retrieve information regarding the binding properties of atorvastatin. Results: Among patients with SLE, the proportion of Th17 (CD4+IL17+) cells was higher compared with controls after activation, with Th17 or Treg polarizing cytokines, phorbol myristate acetate, and ionomycin. In contrast, Treg cells (CD4+CD25+CD127dim/−) frequencies were lower. CD95 stimulation induced relatively more apoptosis in Treg cells and less in Th17 cells, as compared with controls. Addition of atorvastatin normalized Th17/Treg cell balance and apoptosis induction. Accordingly, the ratio of RORC/FoxP3 decreased in patients with SLE. Interleukin 17 and interleukin 6 (IL-6) levels were increased in patients with SLE. Atorvastatin interacted strongly with C-reactive protein (CRP) and also significantly with IL-6. Conclusion: There is a higher proportion of Th17 cells and a lower proportion of Treg cells in patients with SLE after activation. Th17 cells were more resistant than Treg cells to CD95-induced apoptosis in SLE. Atorvastatin normalized these effects. Our findings reveal a novel mechanism behind the imbalance of Th17/Treg cells with implications for treatment in SLE. We determine for the first time simulated interaction between atorvastatin, CRP, and IL-6, implying a novel role of atorvastatin. 
  •  
9.
  • Caidahl, Kenneth, 1949, et al. (författare)
  • IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes.
  • 2012
  • Ingår i: International Journal of Cardiology. - : Elsevier BV. - 0167-5273 .- 1874-1754. ; 167:2, s. 464-469
  • Tidskriftsartikel (refereegranskat)abstract
    • Abstract BACKGROUND: Antibodies against proinflammatory phosphorylcholine (anti-PC) seem to be protective and reduce morbidity. We sought to determine whether low levels of immunoglobulin-M (IgM) autoantibodies against PC add prognostic information in acute coronary syndromes (ACS). METHODS: IgM anti-PC titers were measured in serum obtained within 24h of admission from 1185 ACS patients (median age 66years, 30% women). We evaluated major acute cardiovascular events (MACE) and all-cause mortality short- (6months), intermediate- (18months) and long- (72months) terms. RESULTS: Low anti-PC titers were associated with MACE and all-cause mortality at all follow-up times. After adjusting for clinical variables, plasma troponin-I, proBNP and CRP levels, associations remained at all times with MACE, short and intermediate terms also with all-cause mortality. With anti-PC titers below median, adjusted hazard ratios at 18months were for MACE 1.79 (95% confidence interval [CI]: 1.31 to 2.44; p=0.0002) and for all-cause mortality 2.28 (95% CI: 1.32 to 3.92; p=0.003). Anti-PC and plasma CRP were unrelated and added to risk prediction. CONCLUSIONS: Serum IgM anti-PC titers provide prognostic information above traditional risk factors in ACS. The ease of measurement and potential therapeutic perspective indicate that it may be a valuable novel biomarker in ACS.
  •  
10.
  • Carrera-Bastos, Pedro, et al. (författare)
  • C-reactive protein in traditional melanesians on Kitava
  • 2020
  • Ingår i: BMC Cardiovascular Disorders. - : Springer Science and Business Media LLC. - 1471-2261. ; 20:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Population-based levels of the chronic low-grade systemic inflammation biomarker, C-reactive protein (CRP), vary widely among traditional populations, despite their apparent absence of chronic conditions associated with chronic low-grade systemic inflammation, such as type 2 diabetes, metabolic syndrome and cardiovascular disease. We have previously reported an apparent absence of aforementioned conditions amongst the traditional Melanesian horticulturalists of Kitava, Trobriand Islands, Papua New Guinea. Our objective in this study was to clarify associations between chronic low-grade systemic inflammation and chronic cardiometabolic conditions by measuring CRP in a Kitava population sample. For comparison purposes, CRP was also measured in Swedish controls matched for age and gender. Methods: Fasting levels of serum CRP were measured cross-sectionally in ≥ 40-year-old Kitavans (N = 79) and Swedish controls (N = 83). Results: CRP was lower for Kitavans compared to Swedish controls (Mdn 0.5 mg/L range 0.1—48 mg/L and Mdn 1.1 mg/L range 0.1—33 mg/L, respectively, r =.18 p =.02). Among Kitavans, there were small negative associations between lnCRP for CRP values < 10 and total, low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol. Among Swedish controls, associations of lnCRP for CRP values < 10 were medium positive with weight, body mass index, waist circumference, hip circumference and waist-hip ratio and low positive with triglyceride, total cholesterol-HDL cholesterol ratio, triglyceride-HDL cholesterol ratio and serum insulin. Conclusions: Chronic low-grade systemic inflammation, measured as CRP, was lower among Kitavans compared to Swedish controls, indicating a lower and average cardiovascular risk, respectively, for these populations.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 28
Typ av publikation
tidskriftsartikel (28)
Typ av innehåll
refereegranskat (28)
Författare/redaktör
de Faire, U (4)
Frostegård, Johan (4)
Alarcón-Riquelme, Ma ... (2)
Wiman, B (2)
Morgenstern, R (2)
Ajeganova, S (2)
visa fler...
Hafström, I (2)
Fiskesund, R (2)
Su, J. (1)
et al., (1)
Herlitz, Johan, 1949 (1)
Nilsson, P. M. (1)
Ahuja, Rajeev, 1965- (1)
Sjöling, Sara (1)
Hellström, Cecilia (1)
Nilsson, Peter (1)
Sundquist, Kristina (1)
Hallqvist, Johan (1)
Kozyrev, Sergey V. (1)
Truedsson, Lennart (1)
Sánchez, Elena (1)
D'Alfonso, Sandra (1)
Witte, Torsten (1)
Pons-Estel, Bernardo ... (1)
Martin, Javier (1)
Johansson, Cecilia (1)
Pettersson, K (1)
Sun, J. (1)
Bertilsson, Stefan (1)
Åkerfeldt, Torbjörn (1)
Karlsson, Thomas, 19 ... (1)
Hallqvist, J. (1)
Lundberg, I (1)
Shoenfeld, Yehuda (1)
Magnusson, M (1)
Gunnarsson, I (1)
Caidahl, Kenneth, 19 ... (1)
Hamsten, A (1)
Silveira, A. (1)
Steen, J (1)
Rahman, M (1)
Bremme, K (1)
Gallant, Caroline J. (1)
Råstam, Lennart (1)
Delgado-Vega, Angéli ... (1)
Johanneson, B (1)
Alcocer-Varela, J (1)
Granados, J (1)
Svenungsson, E (1)
Sturfelt, G (1)
visa färre...
Lärosäte
Karolinska Institutet (25)
Uppsala universitet (7)
Lunds universitet (3)
Göteborgs universitet (2)
Kungliga Tekniska Högskolan (2)
Stockholms universitet (1)
visa fler...
Södertörns högskola (1)
Högskolan i Borås (1)
visa färre...
Språk
Engelska (28)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (8)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy